EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

Benedikt Niedermaier iD, Tilmann Bochtler iD, Florian Eichhorn, Raffaella Griffo, Laura V Klotz, Michael Allgäuer, Albrecht Stenzinger iD, Helge Bischoff, Marc A Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel und 8 weitere

International Journal of Cancer · 15.09.2026 · 159 (6) · 1510-1520

DOI: 10.1002/ijc.70508 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, online erschienen am 19.04.2026. Verfasst von Benedikt Niedermaier und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Lung Neoplasms. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dietmar Hopp Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have shown promising results in the neoadjuvant treatment of resectable non‐small cell lung cancer. This open‐label, single‐arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab‐paclitaxel in patients with resectable non‐squamous non‐small cell lung cancer. Patients with previously untreated, pathologically confirmed, non‐squamous non‐small cell lung cancer in stage II, IIIA, and select IIIB (T3N2 only) were treated with atezolizumab and carboplatin/nab‐paclitaxel for 3 cycles followed by curative intent surgery. Major pathologic response (MPR) was defined as primary endpoint. 20 patients with histologically confirmed pulmonary adenocarcinoma in TNM‐stage IIA ( n = 1, 5%), stage IIB ( n = 7, 35%), and stage IIIA ( n = 12, 60%) were enrolled and treated according to the study protocol. 151 treatment‐related adverse events were recorded, and 13 patients (65%) had treatment‐related adverse events of grade 3 or higher. There were no grade 5 events. All patients underwent complete anatomical resection (R0). MPR was observed in 9 patients (45%), including 5 (25%) patients with complete pathological response. The proportion of remaining viable tumor showed a significant but weak association to the relative tumor size change in CT ( p = 0.018) and the relative change in SUV max ( p = 0.006). In conclusion, neoadjuvant chemoimmunotherapy with atezolizumab achieved a promising MPR‐rate of 45% while being well tolerated and allowing a safe and complete surgical resection. These results strongly support the further investigation of atezolizumab as preoperative therapy in resectable non‐small cell lung cancer and underline the continued need to develop biomarkers of response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAntibodies, Monoclonal, HumanizedNeoadjuvant TherapyLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedPaclitaxelCarboplatinProspective StudiesAlbuminsAdultNeoplasm StagingPathologic Complete ResponseTreatment Outcome

Stichwörter der Autor:innen

immunotherapylung cancerneoadjuvantpathologic response

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedPaclitaxelCarboplatinAlbumins130-nm albumin-bound paclitaxel

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany.
  • Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Division of Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Department of Medical Oncology, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany.
  • Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Benedikt Niedermaier, Tilmann Bochtler, Albrecht Stenzinger, Michael Thomas

Förderung

  • Dietmar Hopp Stiftung

Zitieren

APA

Niedermaier, B., Bochtler, T., Eichhorn, F., Griffo, R., Klotz, L. V., Allgäuer, M., Stenzinger, A., Bischoff, H., Schneider, M. A., Christopoulos, P., Haberkorn, U., Heussel, C. P., Zoernig, I., Herth, F. J. F., Thomas, M., Rölle, A., Winter, H., Benner, A., Jaeger, D., & Eichhorn, M. E. (2026). Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial. International Journal of Cancer, 159(6), 1510-1520. https://doi.org/10.1002/ijc.70508

Vancouver

Niedermaier B, Bochtler T, Eichhorn F, Griffo R, Klotz LV, Allgäuer M, et al. Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial. International Journal of Cancer. 2026;159(6):1510-1520. doi:10.1002/ijc.70508

BibTeX
@article{Niedermaier2026,
  author = {Niedermaier, Benedikt and Bochtler, Tilmann and Eichhorn, Florian and Griffo, Raffaella and Klotz, Laura V and Allgäuer, Michael and Stenzinger, Albrecht and Bischoff, Helge and Schneider, Marc A and Christopoulos, Petros and Haberkorn, Uwe and Heussel, Claus Peter and Zoernig, Inka and Herth, Felix J F and Thomas, Michael and Rölle, Alexander and Winter, Hauke and Benner, Axel and Jaeger, Dirk and Eichhorn, Martin E},
  title = {Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {6},
  pages = {1510--1520},
  doi = {10.1002/ijc.70508}
}
Kostenlos starten →